Educate Yourself
The Experts answer your questions
EXPERT BIOS
Paul B. Chapman, M.D. His research focus is the development of new therapies for metastatic melanoma and the predictive assays that will identify which patients are expected to respond to specific treatments. He leads clinical trials with monoclonal antibodies as well as novel combinations of signaling pathway inhibitors and immune modulators. He received his M.D. from Cornell, completed a residency at the University of Chicago and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Chapman is a member of the Grant Review Committee of the Melanoma Research Alliance.
|
David E. Fisher, M.D., Ph.D. He is an expert in molecular oncology, studying the biology of melanocytes in order to identify pathways which drive melanomas, and has discovered several human oncogenes. The pathways impacted by UV exposure to skin are incompletely understood, and simultaneously evoke damaging (mutational) and protective (tanning) responses. Both of these processes are studied in animal models as well as in human skin in order to develop strategies that can be medically beneficial. Dr. Fisher is co-chair of the Grant Review Committee of the Melanoma Research Alliance.
|
Allan C. Halpern, M.D., M.Sc. Dr. Halpern's research has focused on melanoma prevention and early detection. His work has included studies of barriers and facilitators of skin cancer screening and skin self examination, the utilization of whole-body digital imaging for melanoma surveillance in high-risk individuals, the development of novel imaging modalities for early detection of skin cancer, and studies of the evolution of nevi (moles) in adolescence. Back to top
|
Anna C. Pavlick, M.D., M.S., B.S.N. Her research focuses upon novel immunologic and targeted therapies for melanoma. She has published on both clinical and translational aspects of melanoma research. She has developed an extensive translational clinical trials program in melanoma which correlates tumor response with biomarkers from serum and tumors. She is a member of several melanoma advisory and editorial boards. In addition, she is the Co-Director of the NYU Medical Oncology Fellowship Training Program and director of the Bellevue Medical Oncology Clinics.
|
Dr. Chapman is a medical oncologist and Head of the Melanoma Section of the Clinical Immunology Service of the Department of Medicine at Memorial Sloan-Kettering Cancer Center.
Dr. Fisher is Chairman of the Department of Dermatology and Director of the Melanoma Program in Medical Oncology at Massachusetts General Hospital and Professor of Pediatric Hematology/Oncology at Harvard Medical School. 
Dr. Halpern is a Board Certified Internist and Dermatologist with a masters of science degree in clinical epidemiology. Dr. Halpern is the Chief, Dermatology Service and Co-Leader of the Melanoma Disease Management Team at Memorial Sloan-Kettering Cancer Center. 
Anna C. Pavlick is an Associate Professor of Medicine and Dermatology at the New York University Cancer Institute in New York. She is the Director of the NYU Melanoma Program and Melanoma Section Head for the New York City NCI/CTEP Phase II Consortium.